

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/247,054	02/09/1999	MICHAEL ANTONIOU	CACO-0045	7091	
34132 7	7590 11/05/2003		EXAMINER		
COZEN O'CONNOR, P.C. 1900 MARKET STREET			FALK, ANNE MARIE		
PHILADELPHIA, PA 19103-3508			ART UNIT	PAPER NUMBER	
			1632		
			DATE MAILED: 11/05/2001	1	

Please find below and/or attached an Office communication concerning this application or proceeding.

					<u> </u>			
		Applic	ation No.	o. Applicant(s)				
		09/247	7,054	ANTONIOU ET AL.	ANTONIOU ET AL.			
Office Action Summary			ner	Art Unit				
			farie Falk, Ph.D.	1632				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
THE N - Exten after: - If the - If NO - Failur - Any re	DRTENED STATUTORY PERIOD FC MAILING DATE OF THIS COMMUNIO sions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this commuperiod for reply specified above is less than thirty (30) period for reply is specified above, the maximum statile to reply within the set or extended period for reply within the set of the	ATION. i 37 CFR 1.136(a). In no nication. days, a reply within the subtry period will apply and ill, by statute, cause the a	event, however, may a rep statutory minimum of thirty (d will expire SIX (6) MONTH application to become ABAI	ly be timely filed 30) days will be considered timely. IS from the mailing date of this cor NDONED (35 U.S.C. § 133).	nmunication.			
1)🖂	Responsive to communication(s) file	d on <u>25 July 200</u> 3	<u>3</u> .					
2a)⊠	This action is FINAL . 2	b) This action	is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims								
4) Claim(s) 26-54 is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5)⊠ Claim(s) <u>26-49 and 52-54</u> is/are allowed.								
6)⊠ Claim(s) <u>50 and 51</u> is/are rejected.								
7)	Claim(s) is/are objected to.							
8)	Claim(s) are subject to restricti	on and/or election	n requirement.					
Application	on Papers							
9)☐ The specification is objected to by the Examiner.								
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
	Applicant may not request that any object	ction to the drawing	(s) be held in abeyan	ce. See 37 CFR 1.85(a).				
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) 🔲 7	he oath or declaration is objected to t	by the Examiner.						
Priority u	nder 35 U.S.C. §§ 119 and 120							
13)🖂	13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☒ None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a)	☐ The translation of the foreign lang	uage provisional	application has bee	n received.				
15)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s)								
1) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PT ation Disclosure Statement(s) (PTO-1449) Pap	•		mmary (PTO-413) Paper No(s ormal Patent Application (PTO				

Application/Control Number: 09/247,054

Art Unit: 1632

DETAILED ACTION

The amendment filed July 25, 2003 has been entered. Claim 39 has been amended.

Claims 26-54 remain pending in the instant application.

The following rejections are reiterated and constitute the complete set of rejections being applied to the instant application. Rejections and objections not reiterated from the previous office action are hereby withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 50 and 51 stand rejected under 35 U.S.C. 112, first paragraph, for reasons of record as applied to Claim 22 in the Office Action of Paper No. 5 (mailed 7/9/99), as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

At pages 2-3 of the response, Applicants argue that Giraldo et al. (2002) and Chow et al. (2002) support *in vivo* expression using constructs similar to those claimed. However, Chow et al. (2002) is exclusively directed to *in vitro* cell culture assays and does not demonstrate *in vivo* gene expression. Furthermore, the references cited are post-filing art and therefore the skilled artisan would not have had the benefit of the teachings of Giraldo et al. (2002) nor Chow et al. (2002). The priority date of the instant application is August 28, 1996.

At page 3 of the response, Applicants further argue that the results reported by Westphal et al. (1998) and Simpson et al. (1996) show that episomal vectors are stably maintained in human cells.

Application/Control Number: 09/247,054 Page 3

Art Unit: 1632

Applicants point to the statement of Westphal et al. for suggesting that the level of persistence may be sufficient to provide a treatment effect or effective upon repetitive administration. However, the statements made in these references are speculative at best and do not demonstrate that a useful *in vivo* effect would be achieved upon administration of the claimed compositions at the time of filing of this application. Again, the cited references are post-filing art and are not suggestive of enablement at the

Conclusion

Claims 26-49 and 52-54 are allowable.

time of filing for in vivo uses of the claimed compositions.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Maric Falk whose telephone number is (703) 306-9155. The examiner can normally be reached Monday through Thursday and alternate Fridays from 10:00 AM to 7:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst, William Phillips, whose telephone number is (703) 305-3482.

Anne-Marie Falk, Ph.D.

Anne - marie Falk ANNE-MARIE FALK, PH.D PRIMARY EXAMINER